These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 18796631

  • 1. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches.
    Hallaert DY, Jaspers A, van Noesel CJ, van Oers MH, Kater AP, Eldering E.
    Blood; 2008 Dec 15; 112(13):5141-9. PubMed ID: 18796631
    [Abstract] [Full Text] [Related]

  • 2. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
    Tromp JM, Geest CR, Breij EC, Elias JA, van Laar J, Luijks DM, Kater AP, Beaumont T, van Oers MH, Eldering E.
    Clin Cancer Res; 2012 Jan 15; 18(2):487-98. PubMed ID: 22128299
    [Abstract] [Full Text] [Related]

  • 3. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.
    Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ, Cohen GM.
    Blood; 2009 Apr 30; 113(18):4403-13. PubMed ID: 19008458
    [Abstract] [Full Text] [Related]

  • 4. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.
    Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG.
    Blood; 2008 Jan 15; 111(2):846-55. PubMed ID: 17928528
    [Abstract] [Full Text] [Related]

  • 5. BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells.
    Sharma A, Singh K, Mazumder S, Hill BT, Kalaycio M, Almasan A.
    Cell Death Dis; 2013 May 16; 4(5):e628. PubMed ID: 23681223
    [Abstract] [Full Text] [Related]

  • 6. Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia.
    Tonino SH, Mulkens CE, van Laar J, Derks IA, Suo G, Croon-de Boer F, van Oers MH, Eldering E, Wang JY, Kater AP.
    Leuk Lymphoma; 2015 May 16; 56(8):2439-47. PubMed ID: 25511680
    [Abstract] [Full Text] [Related]

  • 7. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering.
    Tromp JM, Tonino SH, Elias JA, Jaspers A, Luijks DM, Kater AP, van Lier RA, van Oers MH, Eldering E.
    Oncogene; 2010 Sep 09; 29(36):5071-82. PubMed ID: 20581863
    [Abstract] [Full Text] [Related]

  • 8. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.
    Dicker F, Kater AP, Prada CE, Fukuda T, Castro JE, Sun G, Wang JY, Kipps TJ.
    Blood; 2006 Nov 15; 108(10):3450-7. PubMed ID: 16741250
    [Abstract] [Full Text] [Related]

  • 9. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
    Chiron D, Dousset C, Brosseau C, Touzeau C, Maïga S, Moreau P, Pellat-Deceunynck C, Le Gouill S, Amiot M.
    Oncotarget; 2015 Apr 20; 6(11):8750-9. PubMed ID: 25797245
    [Abstract] [Full Text] [Related]

  • 10. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.
    McCaig AM, Cosimo E, Leach MT, Michie AM.
    Br J Haematol; 2011 Apr 20; 153(2):199-211. PubMed ID: 21352196
    [Abstract] [Full Text] [Related]

  • 11. The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.
    Zhu HJ, Liu L, Fan L, Zhang LN, Fang C, Zou ZJ, Li JY, Xu W.
    Leuk Lymphoma; 2013 Dec 20; 54(12):2712-9. PubMed ID: 23517560
    [Abstract] [Full Text] [Related]

  • 12. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
    Haselager MV, Kielbassa K, Ter Burg J, Bax DJC, Fernandes SM, Borst J, Tam C, Forconi F, Chiodin G, Brown JR, Dubois J, Kater AP, Eldering E.
    Blood; 2020 Dec 17; 136(25):2918-2926. PubMed ID: 32603412
    [Abstract] [Full Text] [Related]

  • 13. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
    Nalluri S, Peirce SK, Tanos R, Abdella HA, Karmali D, Hogarty MD, Goldsmith KC.
    Cancer Biol Ther; 2015 Dec 17; 16(2):276-86. PubMed ID: 25756510
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.
    Petlickovski A, Laurenti L, Li X, Marietti S, Chiusolo P, Sica S, Leone G, Efremov DG.
    Blood; 2005 Jun 15; 105(12):4820-7. PubMed ID: 15728130
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I, Bailón E, Aguilera-Montilla N, Terol MJ, García-Marco JA, García-Pardo A.
    Oncotarget; 2015 Dec 29; 6(42):44832-48. PubMed ID: 26540567
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.